DSIP peptide dosage: dosage table, timing of administration, frequency and research protocols

There is no standard or regulatory-approved dosage for the DSIP peptide. Published human studies have used experimental intravenous protocols under clinical supervision. These cannot be translated into a safe regimen for self-administration. Most human DSIP research was conducted in the 1980s and early 1990s. Researchers typically administered doses in nanomoles per kilogram of body weight rather than as a fixed number of milligrams. The best-documented sleep studies used a slow intravenous administration of 25 nmol/kg. One repeated-administration study used 30 nmol/kg six times over the course of one week [1–6].

These protocols were developed to investigate specific scientific questions under controlled laboratory conditions. They did not determine the recommended dose, maximum tolerated dose, best route of administration or long-term regimen.

This distinction is important because online DSIP protocols often describe subcutaneous or intranasal administration, fixed amounts expressed in micrograms, bedtime use, cycles, and vials labelled as 2 mg, 5 mg, 10 mg or 15 mg. Such practices do not correspond to the methods used in published human studies.

The size of the vial only determines the declared amount of material in the packaging. It is not a dose, the duration of therapy, or proof of pharmaceutical quality. The dosage table below should therefore be treated as a summary of methods used in research, rather than as an individual dosage guide.

Is there a standard dosage for DSIP?

No standard dose of DSIP has been established for sleep, insomnia, withdrawal symptoms, pain, post-exercise recovery, longevity, or any other proposed use.

Before a standard dose is determined for a medicine, dose-escalation studies, pharmacokinetic and pharmacodynamic data, adequately large randomised trials, systematic safety monitoring, and evaluation of the specific formulation by regulatory authorities are usually required.

DSIP has not undergone such a development programme. Historical studies have evaluated only a small number of doses in small groups of participants, typically using intravenous administration. Contemporary research has not established the minimum effective dose, the dose-response relationship in insomnia, the maximum tolerated dose, or how to adjust dosage for age, renal or hepatic function, concomitant medications, pregnancy, or sleep-disordered breathing.

The term „DSIP dosage” may also refer to several different substances. Native DSIP, also known as emideltide, is a nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. Phosphorylated DSIP, truncated analogues, KND-related peptides, preparations containing DSIP, such as Deltaran, and modified fusion peptides designed to cross the blood–brain barrier are distinct research subjects. The dose tested for one form cannot automatically be applied to another.

The presence of the substance in the regulatory database also does not resolve the issue of dosage. The US Food and Drug Administration (FDA) substance registry lists emideltide as a specific chemical substance, but clearly states that the assignment of a Unique Ingredient Identifier does not imply a regulatory review or approval of the substance [7].

DSIP is not a drug approved by the FDA or EMA for the treatment of insomnia. Therefore, there is no approved product characteristic defining an official dose or administration schedule.

DSIP doses used in published studies

The clearest data on dosing in humans come from small-scale studies on sleep and insomnia, in which 25 or 30 nmol/kg of DSIP was administered intravenously.

In the first controlled sleep study in humans, six healthy volunteers received a slow intravenous infusion of 25 nmol/kg in the morning as part of a double-blind, crossover trial. The participants showed an immediate increase in sleep pressure, and subsequent overnight measurements suggested faster sleep onset and greater sleep efficiency. However, the researchers did not observe the typical sedative effect one would expect from a conventional sleeping pill [1].

In another study, six middle-aged people with chronic insomnia were given 25 nmol/kg intravenously. The sleep-inducing effects were mainly evident during the second hour, following a slight increase in arousal observed during the first hour [2]. These very small studies helped to formulate further scientific hypotheses, but did not establish a universal dose.

A 1984 review of insomnia research described improvement after single doses of 25 nmol/kg, a possible cumulative effect upon repeated administration, an effect following morning administration, and a lack of similar benefits with twice-daily dosing [3]. However, the publication summarised several related experiments and included a single case of a higher dose being used without sufficient data to determine a repeatable protocol. It should not therefore be treated as a formal dose-ranging study.

In 1986, 18 people with chronic psychophysiological insomnia received six intravenous doses of 30 nmol/kg over the course of one week, after which the participants were monitored for a further week [4]. The researchers reported a gradual normalisation of certain sleep parameters; however, the study was small and did not provide the comparative data needed to establish a clinical dosing standard.

In a 1987 polysomnographic study, 25 nmol/kg was administered intravenously over four nights as part of a double-blind crossover trial. Although some sleep parameters showed favourable changes, most did not differ significantly from baseline values or from the placebo group. The researchers considered the overall improvement to be of little clinical significance [5].

In 1992, 16 people with chronic insomnia were given 25 nmol/kg intravenously in the afternoon before the third, fourth and fifth nights of the laboratory study. The objective improvement was slight, subjective sleep quality did not improve, and the authors considered a significant therapeutic benefit to be unlikely [6].

DSIP has also been studied in areas other than insomnia. In an uncontrolled trial of withdrawal symptoms, 67 people with alcohol- or opioid-related symptoms received 25 nmol/kg intravenously as the sole experimental intervention. Approximately 27% participants were lost to follow-up or deemed unsuitable for assessment [8]. This study did not establish a dosing regimen for either withdrawal symptoms or sleep disorders, and its design does not allow for a reliable assessment of efficacy.

In a subsequent anaesthetic experiment, 12 women received intravenous bolus doses of 25, 50 or 100 nmol/kg. DSIP was administered once whilst the subjects were awake and again during isoflurane anaesthesia. Unexpectedly, DSIP reduced delta rhythm, and at the lowest dose it appeared to shallow rather than deepen anaesthesia [9]. This finding demonstrates why a sleep-related name or greater exposure should not automatically be equated with a predictable sedative effect.

DSIP dosage table by type of study

The table below sets out the methods used in the studies to enable an accurate comparison between them. The values in micrograms per kilogram are purely chemical calculations based on native DSIP with a molecular weight of approximately 848.8 g/mol [10]. These are not recommended doses. Salts, excipients, glycine-containing preparations, analogues and modified peptides may have different molecular weights and biological properties.

The table shows why combining all the DSIP levels studied into a single „typical range” would be scientifically misleading. Doses varied by more than a factor of ten; routes of administration included slow intravenous infusion, direct administration into the brain and subcutaneous administration in animals, and the researchers analysed a wide variety of outcomes — ranging from sleep patterns to withdrawal symptoms, anaesthesia, oxidative stress and lifespan.

The species, route of administration, formulation and purpose of the study are key elements of any protocol. They must not be overlooked when interpreting the dose.

DSIP dosage in sleep studies

The most commonly studied dose of DSIP in human sleep studies was 25 nmol/kg administered intravenously. However, the fact that this dose has been used in several experiments does not mean that it is a validated clinical dose.

Given that the molecular weight of native DSIP is approximately 848.8 g/mol, one nanomole of DSIP weighs approximately 0.8488 micrograms. This means that 25 nmol/kg corresponds chemically to approximately 21.2 µg/kg, whilst 30 nmol/kg corresponds to approximately 25.5 µg/kg [10].

These calculations are intended solely to convert the units used in historical studies. They do not take into account the form of the peptide salt, purity, degradation, differences in bioavailability between routes of administration, distribution within the body, or individual health risks.

The clinical significance of these doses also remains unclear. At 25 nmol/kg, one study involving six participants showed longer and less fragmented sleep [2], whilst another controlled crossover study revealed changes of little clinical significance [5]. A double-blind study involving 16 participants also failed to show any significant improvement in subjective sleep quality [6].

Simply administering a specific amount to study participants does not, therefore, mean that this is an effective dose. It is merely an experimental exposure used under the specific conditions of that particular study.

There is no contemporary published sleep study establishing a fixed dose in micrograms for adults, a body-weight-dependent subcutaneous regimen, or an intranasal dose. Nor has it been demonstrated that changing the route of administration whilst maintaining the same body weight leads to similar concentrations of DSIP in the blood or brain.

For this reason, the standard amounts commonly found online cannot be regarded as scientifically validated DSIP doses for sleep.

When should you take DSIP, and how long before bedtime?

Published research does not specify a reliable time for administering DSIP before sleep.

The time of administration varied considerably between studies. In the first controlled experiment, a slow intravenous infusion was administered in the morning, after which both daytime sleep ability and subsequent night-time sleep were assessed [1].

In a study involving six individuals with insomnia, DSIP was administered intravenously in relation to observed sleep period. A slight excitation was noted in the first hour, whereas the sleep-promoting effect appeared mainly in the second hour [2].

In a 1992 study, DSIP was administered intravenously in the afternoon before the third, fourth, and fifth laboratory nights [6]. Such diverse methods do not allow for a universal recommendation to be established as to how many minutes before sleep DSIP should be used.

Additional uncertainty is introduced by a 1984 review of studies. According to the authors, morning administration increased daytime activity while simultaneously affecting nocturnal sleep, whereas twice-daily administration failed to reproduce the desired pattern [3].

This observation does not fit the simple model of DSIP as a short-acting sedative whose effect depends primarily on how close to bedtime it was administered. However, the result comes from small, early studies and has not been confirmed in modern circadian rhythm or pharmacokinetic studies.

No sufficiently large randomised human trial has been conducted directly comparing morning, afternoon and bedtime administration. Nor is there an accepted clinical onset time for DSIP administered subcutaneously, nasally or orally. Internet recommendations regarding the timing of use should therefore be treated as extrapolations rather than established research standards.

How often was DSIP administered in the studies?

The frequency of DSIP administration in studies ranged from a single administration to multiple administrations over consecutive days. None of these schedules has been confirmed as optimal.

Single-dose studies were used to evaluate immediate sleep-related effects in healthy volunteers and individuals with insomnia [1,2].

In the repeat-dose studies, four nights with a dose of 25 nmol/kg [5], three afternoon administrations of 25 nmol/kg before consecutive laboratory nights [6], and six administrations of 30 nmol/kg within one week [4] were used, among others.

A 1984 review suggested that changes in sleep structure might accumulate after about four administrations, but at the same time indicated that using DSIP twice a day did not provide any additional benefit [3]. These data are insufficient to establish once-daily, alternate-night or maintenance dosing regimens.

In animal experiments, completely different frequencies were used. Acute sleep studies often involved a single administration prior to EEG monitoring [11–13]. In contrast, in the Deltaran lifespan study, the drug was administered subcutaneously for five consecutive days each month for a significant proportion of the animals’ lives [14].

This long-term, intermittent regimen was intended to study ageing and the incidence of cancer in mice, not to treat sleep disorders in humans. It therefore does not constitute evidence justifying the use of DSIP cycles in humans.

Frequency cannot be considered independently of the route of administration either. A slow intravenous infusion yields a different concentration-time profile than subcutaneous, intranasal or direct brain administration. Without pharmacokinetic data for specific routes of administration, simply copying the number of weekly administrations does not reproduce the original research protocol.

Can DSIP be used every night?

Published studies do not confirm that DSIP can be used safely and effectively every night.

In some studies of insomnia, DSIP was administered over several consecutive study nights [4–6], but these studies were short and involved a very small number of participants.

They were not designed in a way that enables the detection of rare adverse events, tolerance, changes in hormonal signalling, drug interactions, immune reactions, issues related to product contamination, or the effects of exposure lasting weeks or months. There is no reliable long-term safety database regarding the daily use of DSIP.

An early suggestion that repeated administration may cause a cumulative effect does not prove that long-term use every night is beneficial [3]. The apparent cumulative effect may result from delayed biological signalling, changes in sleep schedule, participant expectations, regression to the mean or other factors.

The same publication also indicated that twice-daily administration did not increase sleep benefits. Therefore, increasing the frequency did not simply lead to a greater effect.

Claims that DSIP should be discontinued after a specified number of days, that the development of tolerance requires planned breaks, or that periodic use prevents receptor desensitisation are not supported by controlled human studies. Not even a specific DSIP receptor has been confirmed. Therefore, such regimens should be treated as anecdotal protocol ideas rather than established pharmacological facts.

DSIP cycle length and duration of the studies

Sleep studies in humans typically lasted from a single dose to around one week. However, this does not imply the establishment of a therapeutic „DSIP cycle”.

The term „cycle” is commonly used in the fitness and research peptide communities, but it does not mean the same thing as a scientifically validated treatment regimen.

Small studies involving six participants analysed single doses [1,2]. Monti and colleagues used four test nights [5]. Bes and colleagues administered DSIP prior to three consecutive nights in the laboratory during a five-night experiment [6]. In the 1986 study by Schneider-Helmert, six doses were administered over the course of one week, after which the participants were observed for a further week [4].

The duration of these regimens was part of an experimental study. It does not prove that three, four, six or seven days constitute the optimal treatment cycle.

Longer treatment regimens used in animal experiments addressed entirely different issues. Deltaran was administered to mice for five consecutive days each month, starting from the third month of life until natural death [14]. Other experiments involved short series of treatments during exposure to continuous light, cold, ischaemia or in ageing studies.

None of these studies confirms a DSIP sleep cycle lasting several weeks in humans, nor do they specify how long the interval between cycles should be.

A reliable study of treatment duration would require pre-specified endpoints relating to insomnia, an adequate number of participants, an appropriate comparator, monitoring during and after treatment, and an assessment of insomnia, rebound effects, tolerance, daytime functioning and adverse effects. Such data for DSIP are currently lacking.

DSIP 2 mg, 5 mg, 10 mg and 15 mg: vial size and dose

The DSIP labels ‘2 mg’, ‘5 mg’, ‘10 mg’ or ‘15 mg’ usually refer to the declared total quantity of the substance contained in the vial. They do not specify the quantity for which safety or efficacy following a single administration has been clinically confirmed.

Several different terms are often confused. The size or contents of a vial refer to the declared total mass of the material in the packaging. Concentration refers to the amount of substance per unit of volume after preparation and depends on the final volume and the actual content of the product. A dose refers to the amount administered on a single occasion. Cumulative exposure is the total amount administered over a specified period. Bioavailable exposure, on the other hand, refers to the proportion of the substance that reaches the circulation or the relevant tissue and depends, amongst other things, on the route of administration, formulation, stability, absorption and metabolism.

A 5 mg vial is therefore not automatically a „5 mg dose”. The label does not specify how many administrations should be made from a single vial, nor does it confirm its identity, purity, sterility, potency, stability or freedom from endotoxin contamination. Nor does a larger vial imply stronger scientific evidence or a longer validated cycle.

The quantity stated on a commercial vial should not automatically be equated with the test material used in historical experiments. In human studies, specific synthetic peptide preparations were used under controlled conditions, and doses were usually expressed in nmol/kg.

Native DSIP has a molecular weight of approximately 848.8 g/mol, whereas for DSIP acetate a weight of about 908.9 g/mol is reported [10,15]. The salt form, counterions, water content, purity and the method of reporting peptide content can affect mass calculations. Without proper analytical verification, calculations based solely on the product label may appear precise, even though the actual amount remains uncertain.

For these reasons, the article does not present reconstitution proportions, syringe unit conversions, injection instructions, or recommendations on dividing the vial contents into individual doses. Published DSIP studies do not support such self-administration procedures.

DSIP internet protocols and published research

Most DSIP protocols described on the internet differ from the methods used in peer-reviewed human studies.

Retailers’ websites, forums, social media and communities related to peptides often describe fixed subcutaneous doses expressed in micrograms, administration around bedtime, daily use for several weeks, or alternating periods of use and breaks.

These regimens are often repeated without supporting human pharmacokinetic studies, randomised trials using the same route of administration, or independent verification of the product itself. Repeating the same protocol across multiple websites does not turn an anecdotal regimen into clinical evidence, particularly when sites may be copying information from one another.

Published human sleep studies looked entirely different. Most used approximately 25–30 nmol/kg intravenously under the supervision of researchers [1–6]. Sleep was monitored using polysomnography, and participants were observed according to specific protocols under controlled conditions.

Even under such conditions, the results regarding efficacy were inconsistent. There is no established scientific evidence to show that the fixed subcutaneous dose promoted online provides exposure equivalent to the body-weight-dependent intravenous infusion used in historical studies.

Similar caution is required for intranasal use. Delivery via the nose may vary depending on the formulation, the application device, drop size, nasal anatomy, blockages, application technique and enzymatic degradation. The peer-reviewed studies on insomnia in humans discussed here do not specify a DSIP intranasal dose or a validated concentration for the nasal spray.

Animal nasal experiments or studies on modified fusion peptides designed to cross the blood-brain barrier cannot be directly translated into a human nasal DSIP protocol.

The hierarchy of evidence should therefore remain clear. A controlled human trial using the same molecule and route of administration provides stronger evidence than an uncontrolled report involving human subjects. Animal experiments constitute pre-clinical evidence, receptor and cellular studies provide mechanistic data, whilst online user accounts are anecdotal in nature. Current social media dosage regimens remain at the lowest level of this hierarchy.

Why can't the DSIP dosage calculator determine a safe dose?

A dosing calculator may perform mathematical calculations or take body weight into account, but it cannot replace the missing clinical data needed to determine a safe dose.

Converting nmol/kg to µg/kg requires knowledge of the peptide's molecular mass. For native DSIP, the mathematical relationship is:

µg/kg = nmol/kg × 0.8488

Therefore, 25 nmol/kg corresponds to approximately 21.2 µg/kg, and 30 nmol/kg to approximately 25.5 µg/kg [10].

This is purely a unit conversion. It does not determine whether a given exposure is effective, which route of administration should be used, how much peptide reaches the brain, nor whether a specific preparation actually contains native DSIP of the assumed molecular weight.

The calculator also does not take into account differences in bioavailability. Intravenous administration introduces the material directly into the circulation, whereas subcutaneous, intranasal, and oral administration involve different absorption and degradation processes.

Mathematical calculations will not correct an erroneous label, peptide aggregation, the presence of impurities, differences between salt forms, degradation during storage or microbial contamination. Nor will they account for the type of sleep disorder, cardiovascular status, risk of respiratory disorders, use of sedatives, exposure to alcohol or opioids, pregnancy or other clinical factors, unless a validated DSIP dosing model exists.

Additional uncertainty is created by converting doses from animals to humans. A dose given in µg/kg in mice cannot be safely converted by simply multiplying it by human body weight. Allometric scaling can be useful at an early stage of formal drug development, but it constitutes only a preliminary toxicological estimate and requires subsequent pharmacokinetic studies, safety evaluations and controlled dose-escalation trials.

Therefore, it is not possible to translate the cat studies using 7 nmol/kg administered intracerebroventricularly, the subcutaneous experiment using 120 nmol/kg in cats, or the Deltaran protocol of approximately 100 µg/kg in mice into instructions for human use [11–14].

FAQ: DSIP dosage

What is the standard dose of the DSIP peptide?

There is no standard or approved dose of the DSIP peptide. In historical human sleep studies, 25 nmol/kg intravenously was most commonly used, whilst one repeat-dose study used 30 nmol/kg intravenously [1–6]. These values describe researcher-supervised experiments and are not recommended doses.

What dosage of DSIP has been studied in relation to sleep?

The best-documented human sleep studies used 25 nmol/kg administered via slow infusion or another controlled intravenous method. The results were inconsistent. Some very small early studies reported beneficial changes in sleep, whereas later controlled studies showed limited clinical significance or no significant improvement in subjective sleep quality [1,2,5,6].

When should DSIP be taken before bed?

No validated pre-sleep time interval has been established. In human studies, DSIP has been administered intravenously in the morning, in the afternoon, or near the observed sleep period. In one small study, mild stimulation was observed in the first hour and a sleep-promoting effect mainly in the second hour [2]. However, this result cannot be translated into a general recommendation for the timing of administration by other routes.

How often was DSIP administered in studies on insomnia?

The protocols included a single dose, three or four consecutive study nights, and six doses over the course of one week [1–6]. No study has established an optimal frequency, and there is no reliable data to support long-term use every night.

Can DSIP be used every night for a month?

There are no adequate data from human studies confirming the safety or efficacy of daily use of DSIP for one month. Published studies on insomnia were short-term, involved a small number of participants and typically used supervised intravenous administration. The one-month regimens described online have not been validated in controlled clinical trials.

Is 5 mg the dose of DSIP?

Not necessarily. „5 mg” usually refers to the declared total amount of material in the vial, rather than a validated single-dose amount. The labelling does not specify the protocol, route or frequency of administration; it does not confirm purity; nor does it prove that the material is equivalent to the native DSIP used in the studies.

Are there any clinical differences between the 2 mg, 5 mg, 10 mg and 15 mg DSIP vials?

They differ in the declared total mass of material, but neither vial size determines the clinical dose. A larger vial does not mean greater efficacy, higher potency or a longer safe cycle. The actual content and quality of the product also cannot be determined solely on the basis of the vial size.

Can the test dose of 25 nmol/kg be converted into milligrams?

It can be calculated mathematically using the molecular weight of native DSIP; however, the value obtained still reflects historical exposure in an intravenous study, rather than the recommended dose. Such a conversion does not allow the protocol to be adapted for subcutaneous, intranasal or oral administration, nor does it determine safety for a specific individual.

Has a subcutaneous dose of DSIP for insomnia in humans been published?

The main peer-reviewed studies on insomnia in humans discussed in the literature utilised intravenous administration. Subcutaneous studies on sleep have been conducted on animals, including cats, but these do not specify a subcutaneous dose for humans [13]. The subcutaneous regimens frequently cited online are therefore anecdotal or commercial protocols, rather than validated clinical standards.

Has a nasal dose of DSIP for sleep been published for humans?

The peer-reviewed literature on insomnia in humans discussed here does not specify a validated intranasal dose of DSIP. The results of animal studies, studies on other DSIP analogues or modified fusion peptides cannot be regarded as a basis for an intranasal aerosol protocol for humans.

Does taking body weight into account make the online DSIP calculator reliable?

No. Calculations based on body weight take only one factor into account. They do not determine bioavailability, product identity, equivalence between different routes of administration, dose–response relationships, maximum tolerated exposure, drug interactions, or whether the DSIP is suitable for a particular individual or research question.

What is the safest dosing protocol for DSIP?

No DSIP dosing regimen has been established that could be considered sufficiently safe to be recommended for use on its own. DSIP remains unapproved for the uses discussed, and its efficacy, long-term safety, product quality and route-of-administration-dependent dosing remain uncertain. Persistent sleep problems or withdrawal symptoms should be assessed by a qualified healthcare professional in accordance with recognised diagnostic and therapeutic standards.

Limitations of available data

Available literature regarding dosage does not allow for the establishment of a standard DSIP protocol, as data involving humans are mainly derived from small studies conducted several decades ago and have limited independent replication.

Several favourable reports regarding sleep came from the same research network, whilst subsequent controlled studies showed weak or clinically insignificant effects. The number of participants was too small to adequately assess rare adverse effects or differences between patient subgroups. Long-term exposure was also not adequately investigated.

Routes of administration and formulations represent another significant limitation. Major studies of sleep in humans have used intravenous DSIP, whilst contemporary online discussions focus mainly on other routes of administration.

Native DSIP, DSIP acetate, phosphorylated analogues, Deltaran and modified peptide constructs should not be regarded as interchangeable substances. In animal studies, direct administration into the brain, subcutaneous injections and other routes of administration were also used in species with different physiologies. Direct extrapolation of such doses to humans is therefore inappropriate.

Finally, the dose described in a scientific publication is not the same as the approved or recommended dose. The research methods describe what the scientists tested. This does not automatically imply confirmed clinical efficacy, regulatory approval, pharmaceutical quality or a safe protocol for home use.

If older abstracts do not contain precise information on the duration of the infusion, the formulation or the administration regimen, this data should be marked as unavailable, rather than being reconstructed on the basis of commercial sources or online communities.

Disclaimer

This article summarises published research methods for educational and scientific information purposes only. It does not constitute medical advice, a prescription, instructions for reconstitution or a protocol for administering injections.

Delta sleep-inducing peptide (DSIP/emideltide) is not approved by the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for the treatment of insomnia, sleep improvement, withdrawal symptoms, pain, promoting longevity or any other uses discussed in this article.

The available evidence is limited, mostly comes from older studies and is partly based on preclinical data. No standard human dose, administration time, route of administration, frequency or length of the treatment cycle has been established.

Tables presenting research and mathematical calculations should not be used to plan the self-administration of an unapproved peptide.

References

1. Schneider-Helmert, D., Gnirss, F., Monnier, M., Schenker, J., & Schoenenberger, G. A. (1981). Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behaviour. International Journal of Clinical Pharmacology, Therapy, and Toxicology, 19(8), 341–345. https://pubmed.ncbi.nlm.nih.gov/6895513/
2. Schneider-Helmert, D., & Schoenenberger, G. A. (1981). The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep. Experientia, 37(9), 913–917. https://doi.org/10.1007/BF01971753
3. Schneider-Helmert, D. (1984). DSIP in insomnia. European Neurology, 23(5), 358–363. https://doi.org/10.1159/000115714
4. Schneider-Helmert, D. (1986). Efficacy of DSIP to normalize sleep in middle-aged and elderly chronic insomniacs. European Neurology, 25(6), 448–453. https://doi.org/10.1159/000116050
5. Monti, J. M., Debellis, J., Alterwain, P., Pellejero, T., & Monti, D. (1987). Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs. International Journal of Clinical Pharmacology Research, 7(2), 105–110. https://pubmed.ncbi.nlm.nih.gov/3583493/
6. Bes, F., Hofman, W., Schuur, J., & Van Boxtel, C. (1992). Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients: A double-blind study. Neuropsychobiology, 26(4), 193–197. https://doi.org/10.1159/000118919
7. U.S. Food and Drug Administration. (n.d.). Emideltide: UNII YN28Z5YZ73. Global Substance Registration System. https://precision.fda.gov/uniisearch/srs/unii/yn28z5yz73
8. Dick, P., Grandjean, M. E., & Tissot, R. (1983). Successful treatment of withdrawal symptoms with delta sleep-inducing peptide, a neuropeptide with potential agonistic activity on opiate receptors. Neuropsychobiology, 10(4), 205–208. https://doi.org/10.1159/000118012
9. Pomfrett, C. J. D., Dolling, S., Anders, N. R. K., Glover, D. G., Bryan, A., & Pollard, B. J. (2009). Delta sleep-inducing peptide alters bispectral index, the electroencephalogram and heart rate variability when used as an adjunct to isoflurane anaesthesia. European Journal of Anaesthesiology, 26(2), 128–134. https://doi.org/10.1097/EJA.0b013e32831c8644
10. National Centre for Biotechnology Information. (2026). PubChem compound summary for CID 68816, delta sleep-inducing peptide. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/68816
11. Susić, V., & Masirević, G. (1985). Effects of the delta sleep-inducing peptide on the sleep cycle of cats deprived of paradoxical sleep. Archives Internationales de Physiologie et de Biochimie, 93(4), 271–277. https://doi.org/10.3109/13813458509079606
12. Susić, V., Masirević, G., & Totić, S. (1987). Effects of delta sleep-inducing peptide on wakefulness and sleep patterns in the cat. Brain Research, 414(2), 262–270. https://doi.org/10.1016/0006-8993(87)90006-0
13. Susić, V. (1987). Effects of subcutaneous administration of delta sleep-inducing peptide on the sleep-waking cycle in the cat. Physiology & Behavior, 40(5), 569–572. https://doi.org/10.1016/0031-9384(87)90098-9
14. Popovich, I. G., Voitenkov, B. O., Anisimov, V. N., Ivanov, V. T., Mikhaleva, I. I., Zabezhinski, M. A., Alimova, I. N., Baturin, D. A., Zavarzina, N. Y., Rosenfeld, S. V., Semenchenko, A. V., & Yashin, A. I. (2003). Effect of delta-sleep inducing peptide-containing preparation Deltaran on biomarkers of ageing, life span and spontaneous tumour incidence in female SHR mice. Mechanisms of Ageing and Development, 124(6), 721–731. https://doi.org/10.1016/S0047-6374(03)00082-4
15. National Centre for Biotechnology Information. (2026). PubChem compound summary for CID 163337005, DSIP acetate. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/163337005